Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by